-
Company Profile
![]()
Heidelberg Pharma AG – Company Profile
Heidelberg Pharma AG (Heidelberg Pharma) is a biopharmaceutical company that develops novel therapeutics for the treatment and specific detection of various cancers. Heidelberg Pharma’s pipeline products are focused on treating multiple myeloma, prostate cancer, hematological cancers, non-hodgkin lymphoma, blood cancers, generic diseases and solid tumors. Through its subsidiary, Heidelberg Pharma Research GmbH provides preclinical contract research services and to develop the toxin Amanitin into oncology therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform. Heidelberg Pharma is headquartered...
Add to Basket -
Company Profile
New![]()
10X Genomics Inc – Company Profile
10X Genomics Inc (10X Genomics) develops an innovative genomics platform. The company’s product pipeline comprises the Chromium X series, chromium connect, and chromium controller. It offers services such as single-cell gene expression, single-cell immune profiling, fixed RNA profiling, single-cell multi-home ATAC + gene expression, spatial gene expression, and targeted gene expression. The company also provides Barcode technology which is compatible with Single Cell Gene Expression and Immune Profiling solutions allowing researchers to simultaneously measure multiple analytes, such as protein and...
Add to Basket -
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – AVC-001
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry AVC-001 Drug Details AVC-001 (GEM-3PSCA) is under development for the treatment of solid tumors...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – HDP-101
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry HDP-101 Drug Details HDP-101 is under development for the treatment of relapsed/refractory multiple myeloma,...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.